FIELD: medicine; pharmaceuticals.
SUBSTANCE: disclosed is a method for autoantigen vaccination in a human patient, where a dose with an effective amount of autoantigen is used in a patient to induce a primary immune response, characterized by that the patient is subjected to a booster application of the above autoantigen, where the amount of autoantigen in a dose for booster application is higher than the amount of autoantigen in a dose used for the purpose of the primary immune response.
EFFECT: what is presented is a method for autoantigen vaccination in a human patient.
21 cl, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PCSK9 VACCINES | 2015 |
|
RU2698971C2 |
| COMPOSITION FOR STIMULATION AND ENHANCEMENT OF PRODUCTION OF ANTIBODY THAT RECOGNIZE GANGLIOSIDE | 1994 |
|
RU2174013C2 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE | 2013 |
|
RU2696566C2 |
| MODIFIED VARIANT OF ANKARA VACCINA VIRUS | 2001 |
|
RU2290438C2 |
| IMMUNOSTIMULATING OLIGONUCLEOTIDES | 2009 |
|
RU2477753C2 |
| COMPOSITIONS OF PEPTIDE CONJUGATE AND METHODS FOR PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE | 2006 |
|
RU2406529C2 |
| IMMUNOSTIMULATORY OLIGONUCLEOTIDES | 2012 |
|
RU2610690C2 |
| COMBINED CHEMOTHERAPY AND IMMUNOTHERAPY | 2006 |
|
RU2473560C2 |
| AMYLOID CONJUGATE, ITS APPLICATIONS AND METHODS | 2017 |
|
RU2712750C1 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF ALZHEIMER-TYPE DEMENTIA | 2013 |
|
RU2811687C2 |
